New 8K

$Incannex Healthcare (IXHL.US)$ Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance

Sheet and Financial Flexibility

In addition to the A$6.0 million refund received, the Company expects a further approximately A$5.1

million in R&D Tax Incentive proceeds later this year, bringing total expected non-dilutive funding under

the program to more than A$11.1 million received in 2026.

NEW YORK and MELBOURNE, Australia, 10 June – Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative combination therapies and psychedelic-assisted treatments, is pleased to announce that it has received A$6,039,162.43 under the Australian Government’s Research and Development Tax Incentive Program.

The Company also expects to receive an additional approximately A$5.1 million in future R&D Tax Incentive proceeds to be received in 2026. Combined, these proceeds represent more than A$11.1 million in non-dilutive capital that further strengthens the Company’s balance sheet and enhances financial flexibility as Incannex advances its clinical development programs and executes on shareholder-focused capital allocation initiatives.

Highlights:

● Received A$6.0 million under the Australian Government’s Research and Development Tax Incentive Program

● Additional approximately A$5.1 million expected to be received in future R&D Tax Incentive proceeds

● More than A$11 million in total non-dilutive capital expected to be received

● Further strengthens Company’s already robust balance sheet

● Provides additional flexibility to support advancement of key clinical assets, including IHL-42X and PSX-001

● Supports ongoing capital allocation initiatives, including the Company’s active share repurchase program

The Australian Government’s Research and Development Tax Incentive Program is designed to encourage innovation and scientific advancement by providing eligible companies with a cash refund for qualifying research and development activities conducted in Australia.

Importantly, the proceeds are non-dilutive in nature, allowing Incannex to recover a significant portion of eligible research and development expenditure without issuing additional shares or taking on debt.

Joel Latham, President and Chief Executive Officer of Incannex Healthcare, commented:

“The receipt of more than A$6 million in non-dilutive capital is another important milestone for Incannex and further strengthens what we believe is one of the strongest balance sheets among clinical-stage biotechnology companies of our size.

“Importantly, these proceeds are being received without issuing a single additional share. At a time when many biotechnology companies are reliant on dilutive financings to fund development activities, Incannex continues to strengthen its balance sheet through disciplined capital management and strategic utilization of government innovation incentives.

“Combined with our existing cash position and debt-free balance sheet, these proceeds provide additional flexibility as we continue advancing our key clinical programs, including the recently commenced DReAMzz study for IHL-42X, while also supporting shareholder-focused capital allocation initiatives such as our active share repurchase program.

“We believe the market continues to significantly undervalue the strength of our balance sheet, the progress across our clinical programs and the multiple value creation opportunities ahead of us. The receipt of this additional non-dilutive capital further reinforces our ability to execute on our strategy while maintaining a strong financial foundation.”

ยอดชม 12K ครั้ง